2025年1月8日乳腺癌文献共享

学术   2025-01-08 16:00   上海  

Nat Med. 2025 Jan 7. IF: 58.7
Nationwide real-world implementation of AI for cancer detection in population-based mammography screening.
www.nature.com/articles/s41591-024-03408-6

J Clin Oncol. 2025 Jan 7. IF: 42.1
Fulvestrant Versus Anastrozole in Endocrine Therapy-Naive Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.
www.ascopubs.org/doi/10.1200/JCO.24.00994

Adv Mater. 2025 Jan 6. IF: 27.4
Fe/Mo-Based Lipid Peroxidation Nanoamplifier Combined with Adenosine Immunometabolism Regulation to Augment Anti-Breast Cancer Immunity.
www.onlinelibrary.wiley.com/doi/10.1002/adma.202419120

Nat Commun. 2025 Jan 6;16(1):420. IF: 14.7
Selectively expressed RNA molecules as a versatile tool for functionalized cell targeting.
www.nature.com/articles/s41467-024-55547-6

J Am Chem Soc. 2025 Jan 7. IF: 14.4
The Midas Touch by Iridium: A Second Near-Infrared Aggregation-Induced Emission-Active Metallo-Agent for Exceptional Phototheranostics of Breast Cancer.
pubs.acs.org/doi/10.1021/jacs.4c15150

Small. 2025 Jan 6. IF: 13.0
Photoexcited Electro-Driven Reactive Oxygen Species Channeling for Precise Extraction of Biomarker Information from Tumor Interstitial Fluid.
www.onlinelibrary.wiley.com/doi/10.1002/smll.202410358

Int J Surg. 2025 Jan 7. IF: 12.5
Artificial Intelligence Predicts Multiclass Molecular Signatures and Subtypes Directly From Breast Cancer Histology: a Multicenter Retrospective Study.
www.lww.com/10.1097/JS9.0000000000002220

Adv Healthc Mater. 2025 Jan 6. IF: 10.0
Engineered IL-21-Expressing Nanovesicles for Co-Delivery of GOX and Ferrocene to Induce Synergistic Anti-Tumor Effects.
www.onlinelibrary.wiley.com/doi/10.1002/adhm.202403477

eClinicalMedicine. 2024 Oct 24;76:102906. IF: 9.6
Breast cancer-the impact of conflict and displacement.
www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00485-1

NPJ Breast Cancer. 2025 Jan 7;11:2. IF: 5.9
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).
www.nature.com/articles/s41523-024-00708-5







































SIBCS
上海国际乳腺癌论坛(Shanghai International Breast Cancer Symposium)
 最新文章